Dennis C Bigg

This inventor holds 23 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Synthelabo, Pierre Fabre Medicament. Active years: 1981-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis C Bigg. Retrieved from https://idiyas.com/inventor/dennis-c-bigg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 8

Forward Citations = 144(Granted Patents)

Location History:

Marsillargues, FR (1982)
Paris, FR (1985)
Jouy en Josas, FR (1981 - 1986)
Castres, FR (1990 - 1997)

Company Filing History:

Pierre Fabre Medicament

patents

Years Active: 1981-1997

Loading Chart...

Areas of Expertise:

Quinoxaline Derivatives

Thiazole Derivatives

Piperidine Compounds

Alkaloid Derivatives

Sulfonamides

Urea Derivatives

Isoindole Derivatives

Phenethyl Derivatives

Spirocyclic Compounds

Imidazoline Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5633255 - 1,2-dihydro-2-oxo-3-aminoquinoxaline derivatives, their preparation and (1997-05-27),

2. 5620985 - Antimitotic binary alkaloid derivatives from catharanthus roseus (1997-04-15),

3. 5385931 - Sulfonamides derived from benzocyclic or benzoheterocyclic acids, their (1995-01-31),

4. 5308844 - Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones and (1994-05-03),

5. 5288758 - New urea derivatives, their preparation and their application in therapy (1994-02-22),

6. 5286735 - Derivatives of 4-aminomethylpiperidine, their preparation and their use (1994-02-15),

7. 5254554 - 3-hydroxy-substituted-1-phenyl-1,4-dihydro-4-oxopyridazines and (1993-10-19),

8. 5198441 - Derivatives of 1,2-dihydro 2-oxo quinoxalines, their preparation and (1993-03-30),

9. 5192763 - [(1-arylpyrrolidin-2-yl)methyl]piperazine derivatives, their preparation (1993-03-09),

10. 5182273 - Spirocyclic N, O derivatives of cyclotriphosphazenes and their use in (1993-01-26),

11. 5081128 - 2,3-dihydro-1H-isoindole derivatives and their application in therapy (1992-01-14),

12. 5059599 - Derivatives of 1-phenyl 1,4-dihydro 3-amino 4-oxo pyridazines, their (1991-10-22),

13. 5034541 - Method of preparing (1991-07-23),

14. 4977159 - 2-[(4-piperidyl)methyl]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (1990-12-11),

15. 4904684 - 2-(4,5-dihydro-1H-imidazol-2-yl)-1,2,4,5-tetrahydropyrrolo[3,2,1 (1990-02-27),

Title: Pioneering Inventor Dennis C Bigg: Crafting a Legacy of Innovation

Introduction: Dennis C Bigg's unwavering dedication to innovation and his relentless pursuit of excellence have cemented his status as a pioneering inventor in the realm of technology. His ingenuity continues to serve as a beacon of inspiration for future generations of inventors, urging them to push boundaries and devise solutions with a lasting societal impact.

Latest Patents: Among his vast array of 23 patents, some of Dennis C Bigg's latest groundbreaking inventions include the development of 1,2-dihydro-2-oxo-3-aminoquinoxaline derivatives and antimitotic binary alkaloid derivatives sourced from catharanthus roseus.

Career Highlights: Throughout his illustrious career, Dennis C Bigg has left an indelible mark on the industry through his work at renowned companies such as Synthelabo and Pierre Fabre Medicament. His innovative spirit and forward-thinking approach have propelled him to the forefront of technological advancement.

Collaborations: Collaborating with esteemed colleagues like Mireille Sevrin and Claude C Morel, Dennis C Bigg has fostered a culture of creativity and collaboration, leading to the development of cutting-edge inventions that have revolutionized the field of technology.

Conclusion: Dennis C Bigg's exceptional contributions to the world of innovation stand as a testament to his unwavering commitment to pushing boundaries and reshaping the technological landscape. His legacy serves as a beacon of inspiration for aspiring inventors, encouraging them to embrace ingenuity and drive positive change through their inventive pursuits.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]